Urothelial Cancer

The FDA has granted accelerated approval to zongertinib in HER2 TKD–mutated NSCLC, full approval to an encorafenib combination in BRAF V600E+ mCRC, and more.

In SunRISe-2, Gem-iDRS plus cetrelimab did not improve BI-EFS vs chemoradiotherapy in bladder-sparing MIBC and the trial stopped early for futility.

An analysis of RETAIN-1 and RETAIN-2 showed ctDNA was prognostic for metastatic recurrence in MIBC.

Alan H. Bryce, MD, discusses the implications of the FDA’s full approval of rucaparib for BRCA mutation–associated mCRPC.

Disitamab vedotin elicited response rates over 50% in previously treated HER2-expressing advanced urothelial carcinoma.

Perioperative enfortumab vedotin plus pembrolizumab improved EFS and OS in cisplatin-eligible muscle-invasive bladder cancer.

Survey results highlight the top RCC and bladder cancer abstracts to watch at the 2026 Genitourinary Cancers Symposium.

In IMvigor011, adjuvant atezolizumab drove ctDNA clearance and improved DFS in ctDNA-positive muscle-invasive bladder cancer.

The top 5 OncLive TV videos of the week cover insights in genitourinary cancers, hematologic malignancies, colorectal cancer, and sarcoma.

Five-year data from CheckMate 274 continued to show a durable DFS benefit with adjuvant nivolumab in high-risk MIUC.

Experts preview key bladder, kidney, and prostate cancer trials to watch at the 2026 Genitourinary Cancers Symposium.

The European Commission has approved nogapendekin alfa inbakicept plus BCG in BCG-unresponsive NMIBC with CIS, with or without papillary tumors.

The FDA approves pembrolizumab regimen in select ovarian cancer, the agency clears Optune Pax for pancreatic cancer, and more this week.

Bladder cancer experts share the most anticipated abstracts expected at the 2026 Genitourinary Cancers Symposium.

Jad Chahoud, MD, MPH, discusses key kidney cancer abstracts to watch at the 2026 ASCO Genitourinary Cancers Symposium.

The top 5 OncLive TV videos of the week cover insights in acute lymphoblastic leukemia, breast cancer, urothelial cancer, ovarian cancer, and follicular lymphoma.

Real-world enfortumab vedotin dose reductions reduced treatment interruptions without significantly affecting OS in advanced urothelial carcinoma.

Ryan D. Chow, MD, PhD, Ronac Mamtani, MD, MSCE, and Ramy Sedhom, MD, spotlight a real-world analysis of upfront enfortumab vedotin dose reduction in bladder cancer.

The resubmission of an sBLA of nogapendekin alfa inbakicept plus BCG in BCG-unresponsive, papillary-only NMIBC was discussed with the FDA.

Andrea Necchi, MD, PhD, discusses data from GDFather-NEO evaluating nivolumab plus visugromab in cisplatin-ineligible MIBC.

The FDA approval of perioperative enfortumab vedotin plus pembrolizumab reshapes curative-intent care for cisplatin-ineligible MIBC.

Anamorelin plus chemotherapy was well tolerated and potentially associated with efficacy in metastatic urothelial carcinoma.

Treatment with nogapendekin alfa inbakicept plus BCG prolonged duration of complete response compared with BCG alone in patients with BCG-naive NMIBC.

Andrea Necchi, MD, dives into the details of the SunRISe-4 trial findings, implications, and ways that utDNA and ctDNA may operate as biomarkers in MIBC.

The top 5 OncLive TV videos of the week cover insights in lung cancer, bladder cancer, gastrointestinal cancer, and multiple myeloma.